聚乙二醇化艾塞那肽(PB-119)治疗初治2型糖尿病的II期随机对照研究
该II期随机双盲安慰剂对照研究纳入251例初治中国2型糖尿病患者,按1:1:1:1随机接受安慰剂或PB-119 75、150、200 μg皮下注射12周。主要终点为HbA1c自基线至第12周变化,各剂量组HbA1c降幅均显著优于安慰剂,且未发生治疗中出现严重不良事件、严重低血糖或死亡。
要点
- PB-119各剂量组12周HbA1c降幅均显著优于安慰剂。
- 150 μg组HbA1c降幅最大,达-12.89 mmol/mol(-1.18%)。
- 12周内未发生治疗中出现严重不良事件、严重低血糖或死亡。
核心结论
- 在初治中国2型糖尿病患者中,PB-119所有测试剂量12周内疗效优于安慰剂且安全耐受良好。
研究设计与样本
- II期随机、双盲、平行、安慰剂对照研究,纳入251例初治中国2型糖尿病患者,按1:1:1:1随机分组。
- 干预为皮下注射安慰剂或PB-119 75、150、200 μg,疗程12周。
- 主要终点为HbA1c自基线至第12周变化;安全性分析纳入所有至少接受一剂研究药物的患者。
主要发现
- 第12周时,75 μg组HbA1c较安慰剂组平均差异为-7.76 mmol/mol(95%CI -9.23, -4.63,p<0.001),即-0.72%(95%CI -1.01, -0.43)。
- 150 μg组HbA1c平均差异为-12.89 mmol/mol(95%CI -16.05, -9.72,p<0.001),即-1.18%(95%CI -1.47, -0.89)。
- 200 μg组HbA1c平均差异为-11.14 mmol/mol(95%CI -14.19, -7.97,p<0.001),即-1.02%(95%CI -1.30, -0.73)。
- 其他疗效终点在不同时间点也观察到类似结果。
- 未发生治疗中出现严重不良事件、严重低血糖或死亡。
关键数值与推荐
- HbA1c<53 mmol/mol(<7.0%)和≤48 mmol/mol(≤6.5%)的患者比例在第2、4、8、12周作为其他终点评估。
- 主要终点HbA1c变化以基线HbA1c校正后比较。
临床怎么用
- PB-119每周一次皮下注射在初治中国2型糖尿病患者中12周内可显著降低HbA1c,且安全性良好。
- 150 μg剂量在本研究中显示出最大的HbA1c降幅。
局限性
- 本研究为II期研究,样本量251例,疗程12周。
- 研究人群为初治中国2型糖尿病患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Glucagon-like peptide 1 receptor agonists (GLP-1 RA) such as exenatide are used as monotherapy and add-on therapy for maintaining glycaemic control in patients with type 2 diabetes mellitus. The current study investigated the safety and efficacy of once-weekly PB-119, a PEGylated exenatide injection, in treatment-naive patients with type 2 diabetes. METHODS: In this Phase II, randomised, placebo-controlled, double-blind study, we randomly assigned treatment-naive Chinese patients with type 2 diabetes in a 1:1:1:1 ratio to receive subcutaneous placebo or one of three subcutaneous doses of PB-119 (75, 150, and 200 μg) for 12 weeks. The primary endpoint was the change in HbA1c from baseline to week 12, and other endpoints were fasting plasma glucose, 2 h postprandial glucose (PPG), and proportion of patients with HbA1c < 53 mmol/mol (<7.0%) and ≤48 mmol/mol (≤6.5%) at 2, 4, 8 and 12 weeks of treatment. Safety was assessed in all patients who received at least one dose of study drug. RESULTS: We randomly assigned 251 patients to one of the four treatment groups (n = 62 in placebo and 63 each in PB-119 75 μg, 150 μg and 200 μg groups). At the end of 12 weeks, mean differences in HbA1c in the treatment groups were -7.76 mmol/mol (95% CI -9.23, -4.63, p < 0.001) (-0.72%, 95% CI -1.01, -0.43), -12.89 mmol/mol (95% CI -16.05, -9.72, p < 0.001) (-1.18%, 95% CI -1.47, -0.89) and -11.14 mmol/mol (95% CI -14.19, -7.97, p <0 .001) (-1.02%, 95% CI -1.30, -0.73) in the 75 μg, 150 μg and 200 μg PB-119 groups, respectively, compared with that in the placebo group after adjusting for baseline HbA1c. Similar results were also observed for other efficacy endpoints across different time points. There was no incidence of treatment-emergent serious adverse event, severe hypoglycaemia or death. CONCLUSIONS/INTERPRETATION: All tested PB-119 doses had superior efficacy compared with placebo and were safe and well tolerated over 12 weeks in treatment-naive Chinese patients with type 2 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT03520972 FUNDING: The study was funded by National Major Scientific and Technological Special Project for Significant New Drugs Development and PegBio.
引用
- Ji L, Du Y, Xu M, et al. Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study. Diabetologia. 2021. PMID: 33687487. doi:10.1007/s00125-021-05392-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。